OSE Immunotherapeutics S.A.
OSE.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | 3,037.7% | -87.8% | -30.4% | – |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | €0 | -€0 | -€0 | -€0 |
| % Margin | 59% | -785.9% | -71.6% | -52.2% |
| Net Income | €0 | -€0 | -€0 | -€0 |
| % Margin | 53.6% | -1,032.9% | -97% | -64.1% |
| EPS Diluted | 1.72 | -1.18 | -0.96 | -0.93 |
| % Growth | 245.8% | -22.9% | -3.2% | – |
| Operating Cash Flow | €0 | -€0 | -€0 | -€0 |
| Capital Expenditures | -€0 | -€0 | -€0 | -€0 |
| Free Cash Flow | €0 | -€0 | -€0 | -€0 |